Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

resistance evolution

Financiado

Cerrado

Bacterial evolution of hypersensitivity and resistance against antimicrobial pep...

Bacterial evolution of hypersensitivity and resistance against antimicrobial peptides Evolution of resistance towards a single drug simultaneously increases (cross-resistance) or decreases (collateral sensitivity) fitness to multiple other antimicrobial agents. The molecular mechanisms driving cross-resistance are... ver más

31/03/2022

HUN-REN BIOLOGICAL...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

HUNREN SZEGEDI BIOLOGIAI KUTATOKOZPONT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-03-31

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

HUN-REN BIOLOGICAL RESEARCH...

1.85M€ | Lider

LABORATORIOS BELLOCH

961.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EIN2019-103155 NUEVOS ANTIMICROBIANOS DIRIGIDOS CONTRA EL INTERACTOMA HUESP... 10K€ Cerrado

SAF2015-66007-P RIBONUCLEASAS HUMANAS PARA COMBATIR LA RESISTENCIA ANTIMICRO... 95K€ Cerrado

EVORESIN Multidrug resistance and the evolutionary ecology of insect... 1M€ Cerrado

IN-ARMOR THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO... 6M€ Cerrado

MicroREvolution MicroREvolution a high throughput drop based microfluidic... 213K€ Cerrado

CTQ2016-76941-R EL SISTEMA DE SECRECION DE TIPO VI COMO DIANA TERAPEUTICA 62K€ Cerrado

Duración del proyecto: 78 meses Fecha Inicio: 2015-09-28
Fecha Fin: 2022-03-31

Líder del proyecto

HUNREN SZEGEDI BIOLOGIAI KUTATOKOZPONT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Evolution of resistance towards a single drug simultaneously increases (cross-resistance) or decreases (collateral sensitivity) fitness to multiple other antimicrobial agents. The molecular mechanisms driving cross-resistance are relatively well described, but it remains largely unclear how frequently does genetic adaptation to a single drug increase the sensitivity to others and what the underlying molecular mechanisms of collateral sensitivity are. This proposal focuses on studying the bacterial evolution of resistance and collateral sensitivity against antimicrobial peptides (AMPs). Beyond their modulatory roles in the immune system, these naturally occurring peptides provide protection against pathogenic microbes, and are considered as promising novel alternatives to traditional antibiotics. However, there are concerns that evolution against therapeutic AMPs can readily develop and as a by-product this might compromise natural immunity. Our knowledge of these issues is limited due to the shortage of systematic evolutionary studies. Therefore, the three central questions we address are: Do bacteria resistant to multiple antibiotics become hypersensitive to certain antimicrobial peptides? What are the evolutionary mechanisms leading to AMP resistance and to what extent does this process induce cross-resistance/collateral sensitivity against other drugs? Last, are these evolutionary trade-offs predictable based on chemical and functional peptide properties? To investigate these issues rigorously, we integrate tools of laboratory evolution, high-throughput phenotypic assays, functional genomics, and computational systems biology. Our project will provide an insight into the evolutionary mechanisms that drive cross-resistance and collateral sensitivities with the aim to explore the vulnerable points of resistant bacteria. Another goal is to provide guidelines for the future design of antimicrobial peptides with desirable properties against bacterial pathogens.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores